IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Arvest Investments Inc.

Arvest Investments Inc. trimmed its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 7.1% in the fourth quarter, HoldingsChannel.com reports. The firm owned 9,350 shares of the medical research company’s stock after selling 715 shares during the quarter. Arvest Investments Inc.’s holdings in IQVIA were worth $1,837,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in IQV. GSA Capital Partners LLP acquired a new position in IQVIA in the third quarter valued at approximately $230,000. Empowered Funds LLC boosted its holdings in shares of IQVIA by 33.9% in the third quarter. Empowered Funds LLC now owns 3,437 shares of the medical research company’s stock valued at $814,000 after acquiring an additional 871 shares during the period. Thrivent Financial for Lutherans boosted its holdings in shares of IQVIA by 20.6% in the third quarter. Thrivent Financial for Lutherans now owns 43,177 shares of the medical research company’s stock valued at $10,231,000 after acquiring an additional 7,369 shares during the period. Pathstone Holdings LLC boosted its holdings in shares of IQVIA by 4.8% in the third quarter. Pathstone Holdings LLC now owns 14,492 shares of the medical research company’s stock valued at $3,434,000 after acquiring an additional 667 shares during the period. Finally, Caprock Group LLC boosted its holdings in shares of IQVIA by 11.7% in the third quarter. Caprock Group LLC now owns 3,003 shares of the medical research company’s stock valued at $712,000 after acquiring an additional 315 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on IQV shares. JPMorgan Chase & Co. decreased their price objective on IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a report on Tuesday, February 18th. UBS Group decreased their price objective on IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a report on Friday, February 7th. Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a report on Monday, February 10th. Truist Financial reissued a “buy” rating and issued a $263.00 price objective (up from $261.00) on shares of IQVIA in a report on Monday, February 10th. Finally, StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th. Five equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Trading Down 0.9 %

NYSE:IQV opened at $186.80 on Thursday. The stock has a fifty day moving average price of $195.71 and a two-hundred day moving average price of $209.36. The stock has a market capitalization of $32.93 billion, a price-to-earnings ratio of 24.91, a PEG ratio of 1.99 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a 1 year low of $179.28 and a 1 year high of $256.29.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.